Life Science Investing Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
Life Science Investing Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
Life Science Investing Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
Life Science Investing Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
Life Science Investing STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
Life Science Investing STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
Life Science Investing STAAR Surgical Announces Expiration of "Window Shop" Period; No Competing Acquisition Proposals Received
Life Science Investing Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company's Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
Life Science Investing STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
Life Science Investing STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger
